Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.

Furie R, Petri MA, Strand V, Gladman DD, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups.

Lupus Sci Med. 2014 Jun 26;1(1):e000031. doi: 10.1136/lupus-2014-000031. eCollection 2014.

2.

Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Reply.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW.

Arthritis Rheumatol. 2014 Feb;66(2):480. doi: 10.1002/art.38251. No abstract available.

3.

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.

Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group.

J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1.

4.

Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects.

Cai WW, Fiscella M, Chen C, Zhong ZJ, Freimuth WW, Subich DC.

Clin Pharmacol Drug Dev. 2013 Oct;2(4):349-57. doi: 10.1002/cpdd.54. Epub 2013 Aug 26.

PMID:
27121939
5.

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups.

Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995.

6.

Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study.

Stohl W, Merrill JT, McKay JD, Lisse JR, Zhong ZJ, Freimuth WW, Genovese MC.

J Rheumatol. 2013 May;40(5):579-89. doi: 10.3899/jrheum.120886. Epub 2013 Apr 1.

PMID:
23547209
7.

Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.

Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, Zhong ZJ, Clarke AE; BLISS-52 and -76 Study Groups.

Ann Rheum Dis. 2014 May;73(5):838-44. doi: 10.1136/annrheumdis-2012-202865. Epub 2013 Mar 22.

8.

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.

Dooley MA, Houssiau F, Aranow C, D'Cruz DP, Askanase A, Roth DA, Zhong ZJ, Cooper S, Freimuth WW, Ginzler EM; BLISS-52 and -76 Study Groups.

Lupus. 2013 Jan;22(1):63-72. doi: 10.1177/0961203312465781.

PMID:
23263865
9.

Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.

Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, Tegzov√° D, McKay JD, Avila-Armengol HE, Utset TO, Zhong ZJ, Hough DR, Freimuth WW, Migone TS; BLISS-76 Study Group.

J Rheumatol. 2012 Aug;39(8):1632-40. Epub 2012 Jun 15.

10.

Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.

Merrill JT, Ginzler EM, Wallace DJ, McKay JD, Lisse JR, Aranow C, Wellborne FR, Burnette M, Condemi J, Zhong ZJ, Pineda L, Klein J, Freimuth WW; LBSL02/99 Study Group.

Arthritis Rheum. 2012 Oct;64(10):3364-73. doi: 10.1002/art.34564.

11.

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW; BLISS-52 Study Group; BLISS-76 Study Group.

Arthritis Rheum. 2012 Jul;64(7):2328-37. doi: 10.1002/art.34400.

12.

Novel evidence-based systemic lupus erythematosus responder index.

Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1143-51. doi: 10.1002/art.24698.

13.

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699.

14.

Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected Patients.

Morse GD, Cohn SE, Shelton MJ, Greisberger C, Cox SR, Della-Coletta AA, Freimuth WW, Reichman RC.

Clin Drug Investig. 2003;23(5):323-8.

PMID:
17535044
15.

Effect of Food on the Steady-State Pharmacokinetics of Delavirdine in Patients with HIV Infection.

Morse GD, Fischl MA, Shelton MJ, Cox SR, Thompson L, Della-Coletta AA, Freimuth WW.

Clin Drug Investig. 2003;23(4):255-61.

PMID:
17535038
16.

A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.

Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Post AB, Redfield RR, Davis GL, Neumann AU, Osborn BL, Freimuth WW, Subramanian GM.

Antivir Ther. 2006;11(1):35-45.

PMID:
16518958
17.

A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.

Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, Fiscella M, Yu R, Osborn BL, Cronin PW, Freimuth WW, McHutchison JG, Subramanian GM.

J Hepatol. 2006 Apr;44(4):671-8. Epub 2006 Jan 30.

PMID:
16487617
18.

A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers.

Subramanian GM, Cronin PW, Poley G, Weinstein A, Stoughton SM, Zhong J, Ou Y, Zmuda JF, Osborn BL, Freimuth WW.

Clin Infect Dis. 2005 Jul 1;41(1):12-20. Epub 2005 May 24.

PMID:
15937757
19.

Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients.

Weinfurt KP, Willke RJ, Glick HA, Freimuth WW, Schulman KA.

Med Care. 2000 Apr;38(4):404-10.

PMID:
10752972
20.

Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group.

Joly V, Moroni M, Concia E, Lazzarin A, Hirschel B, Jost J, Chiodo F, Bentwich Z, Love WC, Hawkins DA, Wilkins EG, Gatell AJ, Vetter N, Greenwald C, Freimuth WW, de Cian W.

Antimicrob Agents Chemother. 2000 Nov;44(11):3155-7.

21.

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.

Larder BA, Hertogs K, Bloor S, van den Eynde CH, DeCian W, Wang Y, Freimuth WW, Tarpley G.

AIDS. 2000 Sep 8;14(13):1943-8.

PMID:
10997398
22.

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).

Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW, Para MF, Reichman RC.

Antimicrob Agents Chemother. 2000 Mar;44(3):794-7.

23.

ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team.

Para MF, Meehan P, Holden-Wiltse J, Fischl M, Morse G, Shafer R, Demeter LM, Wood K, Nevin T, Virani-Ketter N, Freimuth WW.

Antimicrob Agents Chemother. 1999 Jun;43(6):1373-8.

24.

Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients.

Borin MT, Cox SR, Herman BD, Carel BJ, Anderson RD, Freimuth WW.

Antimicrob Agents Chemother. 1997 Sep;41(9):1892-7.

25.

Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients.

Borin MT, Chambers JH, Carel BJ, Freimuth WW, Aksentijevich S, Piergies AA.

Antiviral Res. 1997 Jun;35(1):53-63.

PMID:
9224961
26.

Effects of reverse transcriptase inhibitor therapy on the HIV-1 viral burden in semen.

Gilliam BL, Dyer JR, Fiscus SA, Marcus C, Zhou S, Wathen L, Freimuth WW, Cohen MS, Eron JJ Jr.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 May 1;15(1):54-60.

PMID:
9215655
27.

Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate.

Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW.

Clin Pharmacol Ther. 1997 May;61(5):544-53.

PMID:
9164416
28.

Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.

Morse GD, Fischl MA, Shelton MJ, Cox SR, Driver M, DeRemer M, Freimuth WW.

Antimicrob Agents Chemother. 1997 Jan;41(1):169-74.

29.

Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.

Davey RT Jr, Chaitt DG, Reed GF, Freimuth WW, Herpin BR, Metcalf JA, Eastman PS, Falloon J, Kovacs JA, Polis MA, Walker RE, Masur H, Boyle J, Coleman S, Cox SR, Wathen L, Daenzer CL, Lane HC.

Antimicrob Agents Chemother. 1996 Jul;40(7):1657-64.

30.

Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor.

Freimuth WW.

Adv Exp Med Biol. 1996;394:279-89. Review.

PMID:
8815692
31.

Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication.

Malim MH, Freimuth WW, Liu J, Boyle TJ, Lyerly HK, Cullen BR, Nabel GJ.

J Exp Med. 1992 Oct 1;176(4):1197-201.

32.
34.

Soluble factors containing Thy-1 antigen shed from lymphoblastoid cells modulate in vitro plaque-forming cell response.

Freimuth WW, Miller HC, Esselman WJ.

J Immunol. 1979 Jul;123(1):201-8. No abstract available.

PMID:
376740
35.

Thy-1 antigenicity is associated with glycolipids of brain and thymocytes.

Wang TJ, Freimuth WW, Miller HC, Esselman WJ.

J Immunol. 1978 Oct;121(4):1361-5. No abstract available.

PMID:
308963
36.

Release of thy-1.2 and thy-1.1 from lymphoblastoid cells: partial characterization and antigenicity of shed material.

Freimuth WW, Esselman WJ, Miller HC.

J Immunol. 1978 May;120(5):1651-8. No abstract available.

PMID:
77877

Supplemental Content

Loading ...
Support Center